MX379254B - Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pde5. - Google Patents

Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pde5.

Info

Publication number: MX379254B
Authority: MX; Mexico
Prior art keywords: pds5; inhibitor; pharmaceutical formulations; novel pharmaceutical; pharmaceutically acceptable
Prior art date: 2016-02-26

Application number

MX2016002581A

Other languages

English (en)

Spanish (es)

Other versions

MX2016002581A (es

Inventor

Barry Sherman

Chetan Doshi

Keyur Patel

Vinaykumar Lad

Original Assignee

Apotex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-26

Filing date

2016-02-26

Publication date

2025-03-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59684801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX379254(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-02-26 Application filed by Apotex Inc filed Critical Apotex Inc

2016-02-26 Priority to MX2016002581A priority Critical patent/MX379254B/es

2017-02-17 Priority to PCT/IB2017/000242 priority patent/WO2017144973A2/fr

2017-08-25 Publication of MX2016002581A publication Critical patent/MX2016002581A/es

2018-08-24 Priority to CL2018002441A priority patent/CL2018002441A1/es

2025-03-10 Publication of MX379254B publication Critical patent/MX379254B/es

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title 1
101150109441 pds5 gene Proteins 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 1
201000001880 Sexual dysfunction Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
231100000872 sexual dysfunction Toxicity 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

MX2016002581A 2016-02-26 2016-02-26 Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pde5. MX379254B (es)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
MX2016002581A MX379254B (es)	2016-02-26	2016-02-26	Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pde5.
PCT/IB2017/000242 WO2017144973A2 (fr)	2016-02-26	2017-02-17	Formulations pharmaceutiques novatrices comprenant un inhibiteur de pds5
CL2018002441A CL2018002441A1 (es)	2016-02-26	2018-08-24	Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
MX2016002581A MX379254B (es)	2016-02-26	2016-02-26	Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pde5.

Publications (2)

Publication Number	Publication Date
MX2016002581A MX2016002581A (es)	2017-08-25
MX379254B true MX379254B (es)	2025-03-10

Family

ID=59684801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2016002581A MX379254B (es)	2016-02-26	2016-02-26	Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pde5.

Country Status (3)

Country	Link
CL (1)	CL2018002441A1 (fr)
MX (1)	MX379254B (fr)
WO (1)	WO2017144973A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE398451T1 (de) *	2005-08-29	2008-07-15	Teva Pharma	Festes, teilchenförmiges tadalafil mit bimodaler teilchengrössenverteilung
WO2014092661A1 (fr) *	2012-01-18	2014-06-19	Mahmut Bilgic	Formulations particulaires de tadalafil sous forme effervescente
IN2013MU01177A (fr) *	2013-03-28	2015-04-17	Astron Res Ltd

2016
- 2016-02-26 MX MX2016002581A patent/MX379254B/es unknown
2017
- 2017-02-17 WO PCT/IB2017/000242 patent/WO2017144973A2/fr not_active Ceased
2018
- 2018-08-24 CL CL2018002441A patent/CL2018002441A1/es unknown

Also Published As

Publication number	Publication date
CL2018002441A1 (es)	2018-11-16
MX2016002581A (es)	2017-08-25
WO2017144973A3 (fr)	2017-11-23
WO2017144973A2 (fr)	2017-08-31

Similar Documents

Publication	Publication Date	Title
MX2021001096A (es)	2023-01-17	7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
MX384627B (es)	2025-03-14	Forma cristalina de (s)-7-(1-acriloilpiperidin-4-il)-2-(4-fenoxifenil)-4,5,6,7-tetra-hidropirazolo[1,5-a]pirimidin-3-carboxamida, preparacion y usos de la misma
NZ766835A (en)	2023-09-29	Pharmaceutical compounds
SG11201907095UA (en)	2019-08-27	DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
MX2019013643A (es)	2020-02-03	Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona.
TN2019000110A1 (en)	2020-10-05	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2019000107A1 (en)	2020-10-05	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX2020002711A (es)	2020-07-20	Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
WO2011156405A3 (fr)	2012-04-19	Formulations pour pulvérisation orale et méthodes d'administration de sildenafil
WO2014152029A3 (fr)	2014-12-31	Composés d'oxazolo[5,4-c] quinolin-2-one en tant qu'inhibiteurs de bromodomaines
MX347359B (es)	2017-04-06	Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.
GEP20156417B (en)	2015-12-25	Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MX2021014674A (es)	2022-01-11	Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas.
WO2014027975A3 (fr)	2014-05-30	Nouvelles formulations pharmaceutiques administrées par voie orale
MX390132B (es)	2025-03-20	7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
SG10201810660QA (en)	2018-12-28	Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX367913B (es)	2019-09-11	Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1.
NZ754944A (en)	2023-02-24	Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
WO2014027981A3 (fr)	2014-04-03	Formulations de comprimés effervescents de dapoxétine et d'un inhibiteur de pde5
MX2015013155A (es)	2016-04-04	Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
WO2017144973A3 (fr)	2017-11-23	Formulations pharmaceutiques novatrices comprenant un inhibiteur de pds5
MX2020005847A (es)	2020-09-07	Tratamiento del vsr con producto combinado.
NO20062883L (no)	2006-08-18	Fosfodiesterase-V-inhibitorpreparater
MX383514B (es)	2025-03-14	Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]piridazin-4-onas como inhibidores de la proteína quinasa.
MX2016017315A (es)	2017-04-27	Formas de dosificacion farmaceutica.